Estonian medtech company Nanordica Medical has raised €1.6 million to launch wound dressing for fast healing of chronic wounds. The round was led by Estonian fund 2C Ventures, with participation from existing investors, Specialist VC, Superangel, Amalfi, the Health Founders syndicate led by Erki Mölder, and the EstBAN syndicate led by Heidi Kakko and Martin Goroško.
Around 100 million people worldwide have chronic wounds that fail to heal. More than half of these wounds become infected, often leading to severe complications such as sepsis, amputation and death. Diabetic foot ulcers (DFUs) are the leading cause of infections and leg amputations among chronic wounds.
Every 20 seconds, someone with diabetes loses a leg due to amputation. Often called a “silent killer,” DFUs have five-year mortality rates and treatment costs comparable to cancer. Systemic antibiotics are currently the only treatment recommended for infected wounds by DFU treatment guidelines.
However, they often fail to reach wound sites at sufficient concentrations. Their use is also increasingly restricted due to the rise of antimicrobial resistance. Existing antibacterial dressings are not recommended by wound care guidelines largely because most lack clinical evidence. In addition, to effectively treat infection, many antibacterial dressings typically contain high concentrations of antibacterial agents that can delay healing by damaging healthy skin cells.
